Summary | |
---|---|
Symbol | CSPG4 |
Name | chondroitin sulfate proteoglycan 4 |
Aliases | MCSPG; MEL-CSPG; HMW-MAA; melanoma-associated chondroitin sulfate proteoglycan; chondroitin sulfate proteogl ...... |
Chromosomal Location | 15q24.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cell membrane Single-pass type I membrane protein Extracellular side Apical cell membrane Single-pass type I membrane protein Extracellular side Cell projection, lamellipodium membrane Single-pass type I membrane protein Extracellular side Cell surface Note=Localized at the apical plasma membrane it relocalizes to the lamellipodia of astrocytoma upon phosphorylation by PRKCA. Localizes to the retraction fibers. Localizes to the plasma membrane of oligodendrocytes (By similarity). |
Domain |
PF00054 Laminin G domain PF02210 Laminin G domain |
Function |
Proteoglycan playing a role in cell proliferation and migration which stimulates endothelial cells motility during microvascular morphogenesis. May also inhibit neurite outgrowth and growth cone collapse during axon regeneration. Cell surface receptor for collagen alpha 2(VI) which may confer cells ability to migrate on that substrate. Binds through its extracellular N-terminus growth factors, extracellular matrix proteases modulating their activity. May regulate MPP16-dependent degradation and invasion of type I collagen participating in melanoma cells invasion properties. May modulate the plasminogen system by enhancing plasminogen activation and inhibiting angiostatin. Functions also as a signal transducing protein by binding through its cytoplasmic C-terminus scaffolding and signaling proteins. May promote retraction fiber formation and cell polarization through Rho GTPase activation. May stimulate alpha-4, beta-1 integrin-mediated adhesion and spreading by recruiting and activating a signaling cascade through CDC42, ACK1 and BCAR1. May activate FAK and ERK1/ERK2 signaling cascades. |
Biological Process |
GO:0000187 activation of MAPK activity GO:0001525 angiogenesis GO:0006022 aminoglycan metabolic process GO:0006023 aminoglycan biosynthetic process GO:0006024 glycosaminoglycan biosynthetic process GO:0006026 aminoglycan catabolic process GO:0006027 glycosaminoglycan catabolic process GO:0006029 proteoglycan metabolic process GO:0006790 sulfur compound metabolic process GO:0008347 glial cell migration GO:0009100 glycoprotein metabolic process GO:0009101 glycoprotein biosynthetic process GO:0018108 peptidyl-tyrosine phosphorylation GO:0018212 peptidyl-tyrosine modification GO:0030166 proteoglycan biosynthetic process GO:0030203 glycosaminoglycan metabolic process GO:0030204 chondroitin sulfate metabolic process GO:0030205 dermatan sulfate metabolic process GO:0030206 chondroitin sulfate biosynthetic process GO:0030207 chondroitin sulfate catabolic process GO:0030208 dermatan sulfate biosynthetic process GO:0032147 activation of protein kinase activity GO:0033674 positive regulation of kinase activity GO:0042063 gliogenesis GO:0043405 regulation of MAP kinase activity GO:0043406 positive regulation of MAP kinase activity GO:0043410 positive regulation of MAPK cascade GO:0044272 sulfur compound biosynthetic process GO:0044273 sulfur compound catabolic process GO:0045860 positive regulation of protein kinase activity GO:0048514 blood vessel morphogenesis GO:0048771 tissue remodeling GO:0050650 chondroitin sulfate proteoglycan biosynthetic process GO:0050651 dermatan sulfate proteoglycan biosynthetic process GO:0050654 chondroitin sulfate proteoglycan metabolic process GO:0050655 dermatan sulfate proteoglycan metabolic process GO:0050730 regulation of peptidyl-tyrosine phosphorylation GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation GO:0071900 regulation of protein serine/threonine kinase activity GO:0071902 positive regulation of protein serine/threonine kinase activity GO:1901136 carbohydrate derivative catabolic process GO:1901565 organonitrogen compound catabolic process GO:1903510 mucopolysaccharide metabolic process |
Molecular Function | - |
Cellular Component |
GO:0005775 vacuolar lumen GO:0005796 Golgi lumen GO:0005924 cell-substrate adherens junction GO:0005925 focal adhesion GO:0016324 apical plasma membrane GO:0030027 lamellipodium GO:0030055 cell-substrate junction GO:0031252 cell leading edge GO:0031253 cell projection membrane GO:0031256 leading edge membrane GO:0031258 lamellipodium membrane GO:0043202 lysosomal lumen GO:0045177 apical part of cell |
KEGG | - |
Reactome |
R-HSA-1971475: A tetrasaccharide linker sequence is required for GAG synthesis R-HSA-2024101: CS/DS degradation R-HSA-2022870: Chondroitin sulfate biosynthesis R-HSA-1793185: Chondroitin sulfate/dermatan sulfate metabolism R-HSA-4420332: Defective B3GALT6 causes EDSP2 and SEMDJL1 R-HSA-3560801: Defective B3GAT3 causes JDSSDHD R-HSA-3560783: Defective B4GALT7 causes EDS, progeroid type R-HSA-3595174: Defective CHST14 causes EDS, musculocontractural type R-HSA-3595172: Defective CHST3 causes SEDCJD R-HSA-3595177: Defective CHSY1 causes TPBS R-HSA-2022923: Dermatan sulfate biosynthesis R-HSA-1643685: Disease R-HSA-3560782: Diseases associated with glycosaminoglycan metabolism R-HSA-3781865: Diseases of glycosylation R-HSA-1630316: Glycosaminoglycan metabolism R-HSA-1638091: Heparan sulfate/heparin (HS-GAG) metabolism R-HSA-1430728: Metabolism R-HSA-71387: Metabolism of carbohydrates |
Summary | |
---|---|
Symbol | CSPG4 |
Name | chondroitin sulfate proteoglycan 4 |
Aliases | MCSPG; MEL-CSPG; HMW-MAA; melanoma-associated chondroitin sulfate proteoglycan; chondroitin sulfate proteogl ...... |
Chromosomal Location | 15q24.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between CSPG4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between CSPG4 and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | CSPG4 |
Name | chondroitin sulfate proteoglycan 4 |
Aliases | MCSPG; MEL-CSPG; HMW-MAA; melanoma-associated chondroitin sulfate proteoglycan; chondroitin sulfate proteogl ...... |
Chromosomal Location | 15q24.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of CSPG4 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | CSPG4 |
Name | chondroitin sulfate proteoglycan 4 |
Aliases | MCSPG; MEL-CSPG; HMW-MAA; melanoma-associated chondroitin sulfate proteoglycan; chondroitin sulfate proteogl ...... |
Chromosomal Location | 15q24.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of CSPG4 in various data sets.
|
Points in the above scatter plot represent the mutation difference of CSPG4 in various data sets.
|
Summary | |
---|---|
Symbol | CSPG4 |
Name | chondroitin sulfate proteoglycan 4 |
Aliases | MCSPG; MEL-CSPG; HMW-MAA; melanoma-associated chondroitin sulfate proteoglycan; chondroitin sulfate proteogl ...... |
Chromosomal Location | 15q24.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CSPG4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | CSPG4 |
Name | chondroitin sulfate proteoglycan 4 |
Aliases | MCSPG; MEL-CSPG; HMW-MAA; melanoma-associated chondroitin sulfate proteoglycan; chondroitin sulfate proteogl ...... |
Chromosomal Location | 15q24.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CSPG4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CSPG4. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | CSPG4 |
Name | chondroitin sulfate proteoglycan 4 |
Aliases | MCSPG; MEL-CSPG; HMW-MAA; melanoma-associated chondroitin sulfate proteoglycan; chondroitin sulfate proteogl ...... |
Chromosomal Location | 15q24.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CSPG4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | CSPG4 |
Name | chondroitin sulfate proteoglycan 4 |
Aliases | MCSPG; MEL-CSPG; HMW-MAA; melanoma-associated chondroitin sulfate proteoglycan; chondroitin sulfate proteogl ...... |
Chromosomal Location | 15q24.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of CSPG4 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | CSPG4 |
Name | chondroitin sulfate proteoglycan 4 |
Aliases | MCSPG; MEL-CSPG; HMW-MAA; melanoma-associated chondroitin sulfate proteoglycan; chondroitin sulfate proteogl ...... |
Chromosomal Location | 15q24.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between CSPG4 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | CSPG4 |
Name | chondroitin sulfate proteoglycan 4 |
Aliases | MCSPG; MEL-CSPG; HMW-MAA; melanoma-associated chondroitin sulfate proteoglycan; chondroitin sulfate proteogl ...... |
Chromosomal Location | 15q24.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting CSPG4 collected from DrugBank database. |
There is no record. |